PCL’s proprietary technology, SG CapTM, lets users detect targets in complex biological samples with confidence. SG CapTM employs the properties of sol-gel to capture molecules in a 3D matrix. PCL’s multiplex immunoassay platform harnesses these capabilities to make products like Hi3-1, a blood test for HIV and HCV, with better sensitivity and specificity than that of currently available tests. With more multiplex tests in its pipeline, PCL is positioned to be a leader in multiplex testing.